Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, …

Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …

Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been
associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) …

… The following authors are employees of Merck & Co: Gary A. Herman, Cathy Stevens, Kristien
Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard…

… *Address all correspondence and requests for reprints to: Gary A. Herman, MD, Merck
Research Laboratories, Experimental Medicine, RY34-A4031, 126 East Lincoln Avenue, Rahway, …

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

BACKGROUND:: Dipeptidyl peptidase-IV (DPP-IV) inhibitorsrepresent a new class of oral
antihyperglycemic agents. Sitagliptin is an orally active and selective DPP-IV inhibitor currently …

Mannose-binding proteins have been isolated from the liver of rats and humans and subsequently
been found in the serum of rats, rabbits, and humans. We report the isolation of cDNA …

The effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on ambulatory blood pressure
was assessed in nondiabetic patients with mild to moderate hypertension in a randomized, …